SI1594833T1 - Derivati 1-fenilalkankarboksilne kisline za zdravljenje nevrodegenerativnih bolezni - Google Patents

Derivati 1-fenilalkankarboksilne kisline za zdravljenje nevrodegenerativnih bolezni

Info

Publication number
SI1594833T1
SI1594833T1 SI200430900T SI200430900T SI1594833T1 SI 1594833 T1 SI1594833 T1 SI 1594833T1 SI 200430900 T SI200430900 T SI 200430900T SI 200430900 T SI200430900 T SI 200430900T SI 1594833 T1 SI1594833 T1 SI 1594833T1
Authority
SI
Slovenia
Prior art keywords
treatment
acid derivatives
neurodegenerative diseases
phenylalkanecarboxylic acid
phenylalkanecarboxylic
Prior art date
Application number
SI200430900T
Other languages
English (en)
Inventor
Luca Raveglia
Ilaria Peretto
Stefano Radaelli
Bruno Pietro Imbimbo
Andrea Rizzi
Gino Villetti
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI20030311 external-priority patent/ITMI20030311A1/it
Priority claimed from ITMI20032068 external-priority patent/ITMI20032068A1/it
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of SI1594833T1 publication Critical patent/SI1594833T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C15/00—Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic parts
    • C07C15/12—Polycyclic non-condensed hydrocarbons
    • C07C15/14—Polycyclic non-condensed hydrocarbons all phenyl groups being directly linked
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/65—Halogen-containing esters of unsaturated acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/62—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/40—Unsaturated compounds containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
SI200430900T 2003-02-21 2004-02-19 Derivati 1-fenilalkankarboksilne kisline za zdravljenje nevrodegenerativnih bolezni SI1594833T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITMI20030311 ITMI20030311A1 (it) 2003-02-21 2003-02-21 Acidi 2-fenil-2-dialchil-acetici per il trattamento della malattia di alzheimer.
ITMI20032068 ITMI20032068A1 (it) 2003-10-23 2003-10-23 Derivati dell'acido 1-fenilcicloalcancarbossilico per il trattamento delle malattie neurodegenerative.
EP04712483A EP1594833B1 (en) 2003-02-21 2004-02-19 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
PCT/EP2004/001596 WO2004074232A1 (en) 2003-02-21 2004-02-19 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
SI1594833T1 true SI1594833T1 (sl) 2008-12-31

Family

ID=32910543

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200430900T SI1594833T1 (sl) 2003-02-21 2004-02-19 Derivati 1-fenilalkankarboksilne kisline za zdravljenje nevrodegenerativnih bolezni

Country Status (17)

Country Link
US (3) US7662995B2 (sl)
EP (1) EP1594833B1 (sl)
JP (1) JP4472691B2 (sl)
KR (2) KR101088272B1 (sl)
AT (1) ATE409176T1 (sl)
AU (1) AU2004213145B2 (sl)
BR (1) BRPI0407662B8 (sl)
CA (1) CA2514384C (sl)
CY (1) CY1108514T1 (sl)
DE (1) DE602004016729D1 (sl)
DK (1) DK1594833T3 (sl)
ES (1) ES2312964T3 (sl)
HK (1) HK1087398A1 (sl)
NO (1) NO333118B1 (sl)
PT (1) PT1594833E (sl)
SI (1) SI1594833T1 (sl)
WO (1) WO2004074232A1 (sl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
CA2514384C (en) * 2003-02-21 2012-04-10 Chiesi Farmaceutici S.P.A. 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
CN1946906A (zh) * 2004-04-29 2007-04-11 吉斯通护岸系统股份有限公司 用于墙、护墙和类似物的饰面
WO2006016219A2 (en) 2004-08-03 2006-02-16 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
JP2009502807A (ja) * 2005-07-22 2009-01-29 ミリアド ジェネティクス， インコーポレイテッド 薬剤含有率の高い製剤および投与量形態
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
US8217064B2 (en) 2007-12-20 2012-07-10 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
EP2133322A1 (en) * 2008-06-11 2009-12-16 CHIESI FARMACEUTICI S.p.A. Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
MX2012001411A (es) * 2009-08-04 2012-03-29 Chiesi Farma Spa Proceso para la preparacion de derivados de acido 1-(2-halobifenil-4-il)-ciclopropanocarboxilico.
EP2531511A1 (en) 2010-02-03 2012-12-12 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
WO2011120778A1 (en) * 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Novel polymorphs and salts
WO2011131661A1 (en) * 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives for the therapy of transthyretin amyloidosis
WO2011151330A1 (en) 2010-06-04 2011-12-08 Chiesi Farmaceutici S.P.A. 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the therapy of prion diseases
US9592210B2 (en) 2011-12-22 2017-03-14 Chiesi Farmaceutici S.P.A. 1-phenylalkanecarboxylic acid derivatives for the treatment of cognitive impairment
KR20140144178A (ko) 2012-04-04 2014-12-18 키에시 파르마슈티시 엣스. 피. 에이. 신경퇴행성 질환의 치료를 위한 1-(2-할로-비페닐-4-일)알칸카복실산의 유도체
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2014206898A1 (en) 2013-06-24 2014-12-31 Chiesi Farmaceutici S.P.A. Improved process for the preparation of derivatives of 1-(2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid
EP2818460A1 (en) 2013-06-24 2014-12-31 ZaCh System S.p.A. Cyclopropanation of substituted phenylacetonitriles or phenyl acetates
WO2015109109A1 (en) 2014-01-15 2015-07-23 Forum Pharmaceuticals Inc. Fused morpholinopyrimidines and methods of use thereof
US20150320706A1 (en) 2014-05-12 2015-11-12 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
WO2015181094A1 (en) 2014-05-26 2015-12-03 Chiesi Farmaceutici S.P.A. 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the treatment of down's syndrome
US9802927B2 (en) 2015-06-10 2017-10-31 Denali Therapeutics, Inc. Oxadiazine compounds and methods of use thereof
MX2024002472A (es) 2021-08-31 2024-03-12 Cerespir Incorporated Cocristales.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1933985A1 (de) * 1968-07-04 1970-01-15 Takeda Chemical Industries Ltd Neue Cycloalkancarbonsaeurederivate und Verfahren zu ihrer Herstellung
JPS4994680A (sl) 1973-01-22 1974-09-09
JPS5046669A (sl) 1973-03-28 1975-04-25
JPS58177977A (ja) 1982-04-09 1983-10-18 Grelan Pharmaceut Co Ltd ４−フエニルピラゾ−ル類
WO1996002529A1 (fr) * 1994-07-13 1996-02-01 Taisho Pharmaceutical Co., Ltd. Derive de l'acide thiophene acetique
JPH0994680A (ja) * 1995-07-24 1997-04-08 Toyota Motor Corp 摩擦圧接装置
US5994379A (en) * 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
AU2001257022B2 (en) 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
WO2004064771A2 (en) * 2003-01-14 2004-08-05 Merck & Co., Inc. Geminally di-substituted nsaid derivatives as abeta 42 lowering agents
CA2514384C (en) * 2003-02-21 2012-04-10 Chiesi Farmaceutici S.P.A. 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2006016219A2 (en) * 2004-08-03 2006-02-16 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
EP2133322A1 (en) * 2008-06-11 2009-12-16 CHIESI FARMACEUTICI S.p.A. Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid

Also Published As

Publication number Publication date
CY1108514T1 (el) 2014-04-09
WO2004074232A8 (en) 2005-09-09
KR20110057227A (ko) 2011-05-31
BRPI0407662B8 (pt) 2021-05-25
BRPI0407662A (pt) 2006-03-01
WO2004074232A1 (en) 2004-09-02
ATE409176T1 (de) 2008-10-15
HK1087398A1 (en) 2006-10-13
US8314268B2 (en) 2012-11-20
CA2514384A1 (en) 2004-09-02
US20070060752A1 (en) 2007-03-15
PT1594833E (pt) 2008-12-03
US20110288175A1 (en) 2011-11-24
DK1594833T3 (da) 2008-12-15
AU2004213145B2 (en) 2010-05-13
NO20053855L (no) 2005-11-21
EP1594833B1 (en) 2008-09-24
US8022250B2 (en) 2011-09-20
NO333118B1 (no) 2013-03-04
EP1594833A1 (en) 2005-11-16
CA2514384C (en) 2012-04-10
KR101088272B1 (ko) 2011-11-30
BRPI0407662B1 (pt) 2019-11-12
US7662995B2 (en) 2010-02-16
AU2004213145A1 (en) 2004-09-02
US20100099768A1 (en) 2010-04-22
JP2006518351A (ja) 2006-08-10
DE602004016729D1 (de) 2008-11-06
ES2312964T3 (es) 2009-03-01
NO20053855D0 (no) 2005-08-18
JP4472691B2 (ja) 2010-06-02
KR101152448B1 (ko) 2012-07-02
KR20050104369A (ko) 2005-11-02

Similar Documents

Publication Publication Date Title
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2006035237A3 (en) Methods and compositions relating to alzheimer's disease
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
HRP20130602T1 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
GB0318447D0 (en) Therapeutic agents
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
EP2213684A3 (en) Nogo-a antibodies for the treatment of Alzheimer disease
GB0223038D0 (en) Therapeutic compounds
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
IL216579A0 (en) Aminocyclohexyl ether derivatives and pharmaceutical compositions containing the same
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
MY144616A (en) Substituted dihydroquinazolines
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
HK1104280A1 (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
WO2005003103A3 (en) 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
WO2007017146A3 (en) Use of collismycin and derivatives thereof as oxidative stress inhibitors
IL167848A (en) Use of brimonidine in the manufacture of a medicament for treating neurodegenerative conditions
WO2007048034A3 (en) Use of androgens for the treatment of parkinson' s disease
WO2003024996A3 (de) Antibakterielle makrozyklen
WO2005023288A8 (en) Treatment of fibrotic disease
SI1656372T1 (sl) Spojine 2,4-pirimidindiamina za uporabo pri zdravljenju ali preventivi avtoimunih bolezni